The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease
- Author
- CASTRO-CALDAS, Alexandre1 ; DELWAIDE, Paul2 ; JOST, Wolfgang3 ; MERELLO, Marcelo4 ; WILLIAMS, Adrian5 ; LAMBERTI, Paolo6 ; AGUILAR, Miguel7 ; DEL SIGNORE, Susanna8 ; CESARO, Pierre9
[1] Instituto de Ciências da Saùde, Universidade Católica Portuguesa, Lisboa, Portugal
[2] CHR de la Citadelle, Service de Neurologie, Liège, Belgium
[3] Deutsche Klinik für Diagnostik, Wiesbaden, Germany
[4] Fleni, Instituto de Investigaciones Neurologicas Raul Carrera Montaneses, Buenos Aires, Argentina
[5] Queen Elisabeth Hospital, Neurology Research, Birmingham, United Kingdom
[6] Universvità degli Studi, Clinica Neurologica, Bari, Italy
[7] Hospital Mutua de Terrassa, Servicio de Neurologia, Terrassa, Spain
[8] Institat de Recherches Internationales Servier (IRIS), Courbevoie, France
[9] Service de Neurologie, Centre Hospitalier Universitaire H. Mondor, Créteil, France
Parkinson-Control Study Group - Source
Movement disorders. 2006, Vol 21, Num 4, pp 500-509, 10 p ; ref : 43 ref
- Publisher
- Wiley, Hoboken, NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- Parkinson's disease bromocriptine dopamine agonists levodopa piribedil
- Keyword (fr)
- Bromocriptine Etude double insu Lévodopa Parkinson maladie Piribédil Stimulant dopaminergique Système nerveux pathologie Encéphale pathologie Extrapyramidal syndrome Maladie dégénérative Système nerveux central pathologie
- Keyword (en)
- Bromocriptine Double blind study Levodopa Parkinson disease Piribedil Dopamine agonist Nervous system diseases Cerebral disorder Extrapyramidal syndrome Degenerative disease Central nervous system disease
- Keyword (es)
- Bromocriptina Estudio doble ciego Levodopa Parkinson enfermedad Piribedil Estimulante dopaminérgico Sistema nervioso patología Encéfalo patología Extrapiramidal síndrome Enfermedad degenerativa Sistema nervosio central patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U01 Toxicity: nervous system and muscle
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Discipline
- Drugs toxicity and drug intoxications Neurology Toxicology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17712917
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/mds.20750 
https://dx.doi.org/10.1002/mds.20750
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/mds.20750\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Movement disorders\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mov. disord\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"21\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"500\";s:8:\"\u0000*\u0000epage\";s:3:\"509\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-3185\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CASTRO-CALDAS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Alexandre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"DELWAIDE, Paul\";i:1;s:14:\"JOST, Wolfgang\";i:2;s:16:\"MERELLO, Marcelo\";i:3;s:16:\"WILLIAMS, Adrian\";i:4;s:15:\"LAMBERTI, Paolo\";i:5;s:15:\"AGUILAR, Miguel\";i:6;s:20:\"DEL SIGNORE, Susanna\";i:7;s:14:\"CESARO, Pierre\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/mds.20750\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Movement disorders\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mov. disord\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"21\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"500\";s:8:\"\u0000*\u0000epage\";s:3:\"509\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-3185\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CASTRO-CALDAS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Alexandre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"DELWAIDE, Paul\";i:1;s:14:\"JOST, Wolfgang\";i:2;s:16:\"MERELLO, Marcelo\";i:3;s:16:\"WILLIAMS, Adrian\";i:4;s:15:\"LAMBERTI, Paolo\";i:5;s:15:\"AGUILAR, Miguel\";i:6;s:20:\"DEL SIGNORE, Susanna\";i:7;s:14:\"CESARO, Pierre\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/mds.20750\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/mds.20750\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Movement disorders\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mov. disord\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"21\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"500\";s:8:\"\u0000*\u0000epage\";s:3:\"509\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-3185\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CASTRO-CALDAS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Alexandre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"DELWAIDE, Paul\";i:1;s:14:\"JOST, Wolfgang\";i:2;s:16:\"MERELLO, Marcelo\";i:3;s:16:\"WILLIAMS, Adrian\";i:4;s:15:\"LAMBERTI, Paolo\";i:5;s:15:\"AGUILAR, Miguel\";i:6;s:20:\"DEL SIGNORE, Susanna\";i:7;s:14:\"CESARO, Pierre\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/mds.20750\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Movement disorders\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mov. disord\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"21\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"500\";s:8:\"\u0000*\u0000epage\";s:3:\"509\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-3185\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CASTRO-CALDAS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Alexandre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"DELWAIDE, Paul\";i:1;s:14:\"JOST, Wolfgang\";i:2;s:16:\"MERELLO, Marcelo\";i:3;s:16:\"WILLIAMS, Adrian\";i:4;s:15:\"LAMBERTI, Paolo\";i:5;s:15:\"AGUILAR, Miguel\";i:6;s:20:\"DEL SIGNORE, Susanna\";i:7;s:14:\"CESARO, Pierre\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/mds.20750\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Movement disorders\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mov. disord\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"21\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"500\";s:8:\"\u0000*\u0000epage\";s:3:\"509\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-3185\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CASTRO-CALDAS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Alexandre\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"DELWAIDE, Paul\";i:1;s:14:\"JOST, Wolfgang\";i:2;s:16:\"MERELLO, Marcelo\";i:3;s:16:\"WILLIAMS, Adrian\";i:4;s:15:\"LAMBERTI, Paolo\";i:5;s:15:\"AGUILAR, Miguel\";i:6;s:20:\"DEL SIGNORE, Susanna\";i:7;s:14:\"CESARO, Pierre\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:192:\"The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg\/day) with bromocriptine (25 mg\/day) in early combination with levodopa in parkinson's disease\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
